Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04363437 · ClinicalTrials.gov registry record · Phase 2
COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
A Phase 2 study, sponsored by Maimonides Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04363437 is a Phase 2 study that was terminated before completion, run by Maimonides Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT04363437, a Phase 2 study, was terminated before completion, sponsored by Maimonides Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The most prevalent complication of COVID-19 infection is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality. There is increasing indication that the decompensation in severe COVD-19 infection may be due to a cytokine storm syndrome. This hyperinflammatory syndrome results in a fulminant and fatal hypercytokinemia and multiorgan failure. Approximately 15% of patients with COVID-19 infection are hospitalized and 20-30% of these hospitalized patients require ICU care and/or mechanical ventilation. Overall mortality in hospitalized patients is approximately 20-25%. There is significant interest in therapies that can be given upstream to reduce the rate of mechanical ventilation and thus mortality. We hypothesize that treatment with colchicine in COVID-19 moderate-severe patients may decrease the risk of progression into ARDS requiring increased oxygen requirements, mechanical ventilation, and mortality.
Interventions
- DRUG Colchicine
- DRUG Usual Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-04-26 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04363437
The ClinicalTrials.gov registry entry for NCT04363437 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Colchicine is the first listed.
NCT04363437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04363437 about?
NCT04363437 is a clinical study titled "COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19". The most prevalent complication of COVID-19 infection is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality. There is increasing indication that the decompensation in severe COVD-19 infection may be due to a cytokine storm syndrome. This hyperinflammato...
What is the current status of trial NCT04363437?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2020-04-26. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT04363437?
The interventions under investigation include: Colchicine (DRUG), Usual Care (DRUG).
Who is sponsoring clinical trial NCT04363437?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.